Tanvex BioPharma, Inc. (TPE:6541)

Market Cap	10.72B -19.7%
Revenue (ttm)	483.94M +496.1%
Net Income	-1.42B
EPS	-5.58
Shares Out	264.99M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	337,473
Open	40.85
Previous Close	40.45
Day's Range	40.40 - 41.35
52-Week Range	37.30 - 68.00
Beta	0.22
Analysts	Buy
Price Target	200.85 (+396.54%)
Earnings Date	Aug 13, 2026

About Tanvex BioPharma

Tanvex BioPharma, Inc., a pharmaceutical company, engages in the research, development, manufacture, and sale of biosimilar products in Taiwan and the United States. The company focuses on delivering biopharmaceuticals with biosimilars targeting neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. It also engages in contract development and manufacturing of biological medicines. The company was founded in 2011 and is headquartered in George Town, the Cayman Islands.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 215
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 6541

Financial Performance

In 2025, Tanvex BioPharma's revenue was 400.97 million, an increase of 1056.27% compared to the previous year's 34.68 million. Losses were -1.50 billion, 8.59% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 19, 2026

Data Sources Report a data error